Sabby Management’s BioLineRX BLRX Stock Holding History

Sabby Management’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,250	Closed	-$382K	–	64
2023 Q3	$382K	Buy	+5,250	New	+$353K	0.28%	22
2023 Q1	–	Sell	-43,800	Closed	-$1.03M	–	97
2022 Q4	$1.03M	Sell	43,800 -32,053	-42%	-$953K	0.91%	16
2022 Q3	$2.81M	Buy	+75,853	New	+$4.33M	3.54%	8
2019 Q2	–	Sell	-62	Closed	-$16K	–	92
2019 Q1	$16K	Buy	+62	New	+$18.1K	0.01%	72
2017 Q3	–	Sell	-4,915	Closed	-$2.51M	–	173
2017 Q2	$2.51M	Sell	4,915 -321	-6%	-$165K	0.16%	62
2017 Q1	$3.02M	Buy	+5,236	New	+$3.37M	0.16%	67
2015 Q2	–	Sell	-1,241	Closed	-$1.57M	–	330
2015 Q1	$1.57M	Sell	1,241 -307	-20%	-$378K	0.07%	161
2014 Q4	$1.5K	Buy	+1,548	New	+$1.35M	0.05%	144
2014 Q3	–	Sell	-3,369	Closed	-$4.2M	–	268
2014 Q2	$4.2M	Buy	3,369 +198	+6%	+$248K	0.18%	69
2014 Q1	$4.24M	Buy	+3,171	New	+$5.21M	0.24%	72

Other funds holding BLRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

VFA

Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sabby Management's BLRX Position: Q4 2023 in Review

Sabby Management sold out of BioLineRX (BLRX) in Q4 2023, closing a stake of 5,250 shares — an estimated $382K sold.

Sabby Management first reported a position in BLRX in Q1 2014 and held it in 10 quarters. The position peaked at $4.24M in Q1 2014. 29 funds tracked by Wall St. Rank hold BLRX as of Q4 2023.

Sabby Management reported no remaining BioLineRX position as of Q4 2023 after selling out during the quarter.
Sabby Management sold 5,250 BioLineRX shares in Q4 2023, an estimated $382K.
Sabby Management first reported a position in BioLineRX in Q1 2014 and held it in 10 quarters.
Sabby Management's BioLineRX position peaked at $4.24M in Q1 2014.
29 funds tracked by Wall St. Rank held BioLineRX as of Q4 2023.

Based on Sabby Management's 13F filing for Q4 2023, filed 14 Feb 2024.